Triple Therapy with Azacitidine, Venetoclax and Gilteritinib as a Therapeutic Option for Adult Patients with Refractory/Relapsed FLT3 Mutated Acute Myeloid Leukemia – A Single Center Experience

Introduction: FLT3 mutations occur in approximately 30% of acute myeloid leukemia (AML) cases and are associated with high relapse rates and poor prognosis. While second-generation inhibitors like gilteritinib have improved outcomes in the relapsed/refractory (R/R) setting, therapeutic resistance re...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Dana FRANGU, Roxana HIRJAN, Bianca CONSTANTIN, Andreea ANDRUNACHE, Mihaela CIRSTEA, Bogdan IONESCU, Camelia STANCIOAICA, Alexandra GHIAUR, Aurelia TATIC
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Romanian Society of Hematology 2026-06-01
Seri Bilgileri:	Documenta Haematologica
Konular:	relapsed/refractory acute myeloid leukemia flt3 mutation gilteritinib venetoclax azacitidine triple therapy allogeneic hematopoietic stem cell transplantation
Online Erişim:	https://www.dhrrh.ro/wp-content/uploads/2026/06/DHRRH-2026-2-art2.pdf
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!